Lucid Diagnostics Inc. LUCD
Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026
Lucid Diagnostics Inc. (LUCD) is a healthcare company listed in the US with a market value of about $93M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$61M, a net margin of -1127.2%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -164%.
About Lucid Diagnostics
Lucid Diagnostics is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $500000 in 2021 to $5M in 2025, growth of about 75.2% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 182% over three years (dilution for shareholders). It spends 121% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $5M | $5M | $4M | $2M | $377000 | $500000 | — |
| Net income | -$61M | -$58M | -$46M | -$53M | -$56M | -$28M | -$8M |
| Free cash flow | -$52M | -$47M | -$44M | — | -$33M | -$19M | — |
| EPS (diluted) | $-0.38 | $-0.34 | $-0.53 | $-0.63 | $-0.78 | $-0.76 | $-0.29 |
| Net margin | -1127.2% | -1232.7% | -1047.6% | -2169.1% | -14899.5% | -5615.6% | — |
| ROIC | — | -135.1% | -172.8% | -295.9% | -177.4% | -39.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $4.00, 791% above the current price; targets range from $2.00 to $9.50; the consensus rating is “Strong buy”; expected EPS is $-0.24 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Lucid Diagnostics pay a dividend?
Not currently.
Is Lucid Diagnostics a good stock to buy?
We do not give buy or sell advice. Lucid Diagnostics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.